Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Updation on Bioequivalence (BE) Program- Successful Completion of Phase 1 by ....
KPL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Kwality Pharmaceuticals has successfully completed Phase 1 of its Bioequivalence (BE) program, which covers over 30 molecules across Oncology, Cardiology, Anti-diabetics, and Anti-hypertensives. The program includes both patented and off-patent complex molecules and is being executed with four globally accredited Contract Research Organizations (CROs). In Phase 1, BE studies were successfully completed for three molecules: Hydroxycarbamide, Nilotinib, and Liposomal Amphotericin B. The dossiers for these products are now being prepared for submission across regulated, semi-regulated, and Rest of the World (ROW) markets.
This is a positive operational milestone that strengthens the company's global regulatory pipeline and positions it for future product approvals in key international markets. For shareholders, it signals progress on the company's growth strategy but is not yet revenue-generating and may take time to translate into commercial outcomes.